FDA recall, , Moderate risk
Golden State Medical Supply Carbamazepine Tablets
Carbamazepine Tablets, USP, 200mg have black specks due to CGMP deviations.
Summary by Recall Canary from the FDA notice
What happened
Golden State Medical Supply Inc., of Camarillo, California, recalled Carbamazepine Tablets, USP, 200mg, packaged in 1000-count and 100-count bottles, due to CGMP deviations that caused the tablets to have black specks. The recall began August 7, 2026, and was added to the FDA's Enforcement Report on August 19, 2026. The product was distributed nationwide in the USA.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Affected if its NDC and lot code are listed under that product.
An NDC (National Drug Code) is usually printed on the drug's label.
Carbamazepine Tablets, USP, 200mg
- NDC
- 51407-215-10
- 51407-215-01
- Lot code
- GS067429
- GS068091
Recall details
- Company began the recall
- Sold in
USA Nationwide
- Company
- Golden State Medical Supply Inc.Camarillo, California
- Hazard
- Manufacturing problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99614
- Recall number
- D-0771-2026
- Quantity recalled
- 1200 bottles
All recalls from Golden State Medical Supply Inc.
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
Summary updated
